JAK2 and thyroid cancer: A study on thyroid cancer cells (TCC) indicated ORI targeting JAK2 for deactivating JAK2/STAT3 pathway to ultimately suppress angiogenesis and epithelial–mesenchymal transition of TCC (Liu et al., 2022).